Roche's Divarasib Outperforms Amgen and BMS in Phase 3 Trial, Poised to Lead the Mutated Lung Cancer Market
Roche's Next-Generation Targeted Therapy, Divarasib, Achieves Positive Phase 3 Results
Roche's KRAS G12C inhibitor, divarasib, demonstrated superior clinical efficacy in the Phase 3 Krascendo 1 study, outperforming Amgen's Lumakras (sotorasib) and BMS's Krazati (adagrasib). This open-label trial involved 338 patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC) and established divarasib's superiority through a head-to-head comparison. Roche has garnered significant attention in the market by achieving statistically significant improvements in both the primary endpoint, progression-free survival (PFS), and the key secondary endpoint, overall survival (OS).
Overcoming the Limitations of Existing Treatments and Demonstrating Differentiated Molecular Strengths
Despite being the first KRAS targeted therapies, Lumakras (approved in 2021) and Krazati (approved in 2022) have experienced somewhat stagnant sales growth due to their limited target selectivity and efficacy maintenance. Divarasib demonstrated enhanced drug binding potency and high target selectivity in in vitro studies, showcasing its structural differentiation. These superior molecular-level strengths translated into statistically significant results in the Phase 3 clinical trial, enabling Roche, as a latecomer, to quickly establish a foundation for potentially reshaping the market.
Strategic Design of the Phase 3 Trial and Competition for Standard of Care
Roche made a strategic decision to revise its initial clinical plan, which involved comparing divarasib with the chemotherapy agent docetaxel, and instead opted for a direct comparison with its competitor drugs, Lumakras and Krazati. This aggressive clinical design was based on Roche's strong confidence in the superior therapeutic efficacy of its drug, and it ultimately led to the successful confirmation of its superiority compared to the existing standard of care (SoC). With these clinical results, there is a high probability that the paradigm of lung cancer treatment will rapidly shift towards Roche upon regulatory approval.
Reshaping the Lung Cancer Treatment Market and Prospects for Commercial Value
Roche anticipates peak annual sales of 1 to 2 billion Swiss francs (approximately 1.2 to 2.5 billion U.S. dollars) for divarasib and plans to begin its market entry with the approval for second-line treatment. Roche is currently conducting clinical trials for first-line treatment and adjuvant therapy, which are expected to expand its indications in the long term. With a goal of submitting its application for approval in 2027, Roche's entry into the market is expected to intensify the competition for market share with Amgen and BMS in the KRAS inhibitor market, which is currently valued at hundreds of millions of dollars annually.
Roche's announcement of the top-line data from its Phase 3 Krascendo 1 trial represents a pivotal moment that threatens to disrupt the market dominance of Amgen's Lumakras and BMS's Krazati, which recorded revenues of $363 million and $205 million, respectively, in 2025. In the short term, divarasib, with a target approval date of 2027, is expected to establish itself as a new standard of care (SoC) for patients with second-line NSCLC, where targeted treatment options are limited, thereby changing prescription patterns. In the medium to long term, as Roche pursues clinical expansion for first-line treatment and adjuvant therapy, the global KRAS inhibitor market, projected to grow rapidly to approximately $6.5 billion by 2030, could undergo a major reshuffling. In particular, the demonstration of superior efficacy and selectivity compared to competing drugs in this Phase 3 trial is expected to further intensify research and development competition in the field of precision oncology.